REGN Court Alert: Regeneron Investors Seeking to Recover Losses in Securities Fraud Class Action are Notified to Contact BFA Law before September 14 Deadline
Bleichmar Fonti & Auld LLP announced a class action lawsuit has been filed against Regeneron Pharmaceuticals regarding alleged securities fraud tied to its Phase III Fianlimab-Libtayo clinical trial. The law firm reminds investors of the September 14, 2026 deadline to seek lead plaintiff status in the case pending in the Southern District of New York.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.